Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Infectious Diseases |
Vol/bind | 51 |
Udgave nummer | 5 |
Sider (fra-til) | 611-9 |
Antal sider | 9 |
ISSN | 1058-4838 |
DOI | |
Status | Udgivet - 1 sep. 2010 |
ID: 33863666